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Abstract
Background: Spinal cord stimulation (SCS) is an established treatment for chronic neu-
ropathic, neuropathic-like and ischaemic pain. However, the heterogeneity of patients in 
daily clinical practice makes it often challenging to determine which patients are eligible 
for this treatment, resulting in undesirable practice variations. This study aimed to estab-
lish patient-specific recommendations for referral and selection of SCS in chronic pain.
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1 |  INTRODUCTION
It is estimated that chronic pain affects around 20% of the 
adult population in developed nations (Breivik, Collett, 
Ventafridda, Cohen, & Gallacher, 2006; Dahlhamer et al., 
2018). The management of chronic pain is often complex 
and may consist of pharmacological therapy, surgery, mini-
mally invasive treatments, physiotherapy, psychological and 
behavioural treatments, or combinations thereof (Verrills, 
Sinclair, & Barnard, 2016). Within this therapeutic arsenal, 
spinal cord stimulation (SCS) has gained an established posi-
tion for selected patients.
There is substantial evidence from randomized controlled 
trials (RCTs) on the efficacy of SCS in patients with persist-
ing pain after previous spine surgery (De Andres et al., 2017; 
Kapural et al., 2015; Kumar et al., 2007; North, Kidd, Farrokhi, 
& Piantadosi, 2005), in patients with complex regional pain 
syndrome (CRPS) (Kemler et al., 2000) and in patients with 
painful diabetic neuropathy (van Beek et al., 2018; Slangen 
et al., 2014; de Vos et al., 2014). For other neuropathic pain 
syndromes (NPS), such as postherpetic neuralgia and phantom 
and stump pain, case reports and single-arm studies report pos-
itive effects of SCS, but controlled studies are needed to con-
firm these findings (Corbett et al., 2018; Kurklinksy, Palmer, 
Arroliga, & Ghazi, 2018). RCTs have shown that SCS may also 
be beneficial in ischaemic conditions such as refractory angina 
pectoris (Pan et al., 2017) and critical limb ischaemia (Ubbink 
& Vermeulen, 2013). However, data on the specific effect of 
SCS on the pain component of these conditions are less con-
clusive as these studies typically use other (primary) outcome 
measures (e.g. angina frequency, limb salvage).
The outcome of SCS in patients with chronic pain may 
be negatively affected by several factors including substance 
abuse, psychological distress and mental health problems (De 
La Cruz et al., 2015; Fama et al., 2016). As these problems 
may often be reversible to an acceptable level, adequate iden-
tification and appropriate management, preferably in a multi-
disciplinary setting, are crucial.
The complex interaction of clinical and psychosocial fac-
tors that determine the eligibility of patients with chronic 
neuropathic, neuropathic-like and ischaemic pain for the con-
sideration of SCS has led to a situation in which selection 
criteria are usually opaque for referrers, and often lack consis-
tency among implant centres. The available guidelines (a.o. 
Cruccu et al., 2016; Dworkin et al., 2013; National Institute 
for Health & Clinical Excellence, 2008) are not very explicit 
in their recommendations and certainly do not address the 
heterogeneity of patients seen in daily clinical practice.
This study aimed firstly at establishing patient-specific 
criteria for the appropriate referral and selection for SCS in 
in the design, set-up and conduct of the 
panel study, or in the preparation of this 
manuscript. The manuscript has been 
shared with the funder after submission.
Methods: A multidisciplinary European panel used the RAND/UCLA Appropriateness 
Method (RUAM) to assess the appropriateness of (referral for) SCS for 386 clinical sce-
narios in four pain areas: chronic low back pain and/or leg pain, complex regional pain syn-
drome, neuropathic pain syndromes and ischaemic pain syndromes. In addition, the panel 
identified a set of psychosocial factors that are relevant to the decision for SCS treatment.
Results: Appropriateness of SCS was strongly determined by the neuropathic or 
neuropathic-like pain component, location and spread of pain, anatomic abnormali-
ties and previous response to therapies targeting pain processing (e.g. nerve block). 
Psychosocial factors considered relevant for SCS selection were as follows: lack of 
engagement, dysfunctional coping, unrealistic expectations, inadequate daily activity 
level, problematic social support, secondary gain, psychological distress and unwill-
ingness to reduce high-dose opioids. An educational e-health tool was developed that 
combines clinical and psychosocial factors into an advice on referral/selection for SCS.
Conclusions: The RUAM was useful to establish a consensus on patient-specific 
criteria for referral/selection for SCS in chronic pain. The e-health tool may help 
physicians learn to apply an integrated approach of clinical and psychosocial factors.
Significance: Determining the eligibility of SCS in patients with chronic pain re-
quires careful consideration of a variety of clinical and psychosocial factors. Using 
a systematic approach to combine evidence from clinical studies and expert opinion, 
a multidisciplinary European expert panel developed detailed recommendations to 
support appropriate referral and selection for SCS in chronic pain. These recommen-
dations are available as an educational e-health tool (https://www.scsto ol.org/).
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chronic pain based on the best available evidence from clinical 
studies and the expertise of a European multidisciplinary ex-
pert panel. In addition, we aimed at developing an educational 
e-health tool based on the panel outcomes that allows both 
referrers and implanters to learn about the appropriate (pre)
selection of patients with chronic pain for the consideration of 
SCS, with the eventual goal of improving patient outcomes.
2 |  METHODS
To explore the indications for SCS in patients with chronic 
pain, we used the RAND/UCLA Appropriateness Method 
(RUAM) (Brook et al., 1986). This modified Delphi method 
aims at systematically combining evidence from clinical 
studies and expert opinion to establish patient-specific rec-
ommendations on the appropriateness of medical, surgical 
and diagnostic procedures. The RUAM has been applied 
in various disease areas, and has been extensively tested 
for its reliability and predictive validity (Lawson, Gibbons, 
Ko, & Shekelle, 2012). It is particularly helpful if data from 
clinical studies are insufficient to address the heterogeneity 
of patients in daily clinical practice (Fitch et al., 2001).
2.1 | Panel composition
We composed a European expert panel representing the dis-
ciplines that are commonly involved in the evaluation of pa-
tients for SCS (anaesthesiology, neurosurgery, psychology, 
physiotherapy and nursing). Selection of panel members was 
based on their scientific and/or clinical expertise in the field 
of SCS. The panel consisted of 18 experts from 9 European 
countries (see supporting information).
2.2 | Literature study
A literature study was conducted to establish an overview of 
the evidence from clinical studies on the efficacy and safety of 
SCS for different types of chronic pain, as well as on predic-
tive factors for success or failure. The study results were used 
to shape the study design and to ensure that panellists had 
access to the same body of evidence while doing the ratings.
2.3 | Panel process
The flowchart of the panel process is shown in Figure 1. During 
the first panel meeting (December 2018; Chantilly, France) the 
panel reviewed the results of the literature study and formulated 
the starting points for the study. Selected inclusion and exclu-
sion criteria for the consideration of SCS are listed in Table 1. 
The panel further identified four key indication areas for SCS 
in chronic pain: (a) chronic low back and leg pain (CBLP), 
(b) CRPS, (c) NPS (such as mono- and polyneuropathies) and 
4) Ischaemic Pain Syndromes (IPS). For each of these indica-
tion areas the panel identified specific clinical variables that 
may be relevant for the decision of (referral for) SCS. These 
included treatment history, type/nature and location of pain, 
anatomic abnormalities, response to previous procedures (e.g. 
root block, transcutaneous electrical nerve stimulation [TENS] 
and/or medication) and spread of pain.
Based on these indication areas and variables, a set of 330 
clinical scenarios was compiled. Using an online rating pro-
gram, the panel members were asked to individually assess 
the appropriateness of (referral for) SCS for all scenarios. 
For SCS, no distinction was made between the various types 
of SCS or related therapies (e.g. conventional, burst, HF10, 
dorsal root ganglion [DRG] stimulation). In addition, no dis-
tinction was made between the decision for a trial or direct 
implant, as it was assumed that these decisions are the com-
petence of the implant centres. Furthermore, variation in na-
tional guidelines and health authority requirements prevents 
global recommendations in this respect. A 9-point scale was 
used to express the appropriateness of (referral for) SCS (ref-
erence values: 1 = inappropriate, 5 = equivocal/uncertain and 
9 = appropriate). Panellists were instructed to consider only 
the clinical perspective, and to disregard cost of treatment, 
reimbursement environment and other potential constraints.
The panel discussed the results of the first rating round 
during a second meeting (Amsterdam, March 2019). This led 
to a number of adaptations and refinements of the clinical 
scenarios and related definitions.
The definitions of neuropathic and nociceptive pain re-
ceived much attention. Recently, the International Association 
for the Study of Pain (IASP, 2019) defined the term “noci-
plastic” pain as “pain that arises from altered nociception de-
spite no clear evidence of actual or threatened tissue damage 
causing the activation of peripheral nociceptors or evidence 
for disease or lesion of the somatosensory system causing 
the pain”. Besides nociceptive and neuropathic pain, this is a 
third type of pain descriptor. However, as this term was just 
recently proposed and officially accepted, it is not commonly 
known and may be confusing for non-(pain) specialists. The 
panel therefore elected to replace this term with “neuropath-
ic-like pain” adding “without sensory disturbances”.
The final set comprised 386 scenarios (Table 2) for which 
the appropriateness of (referral for) SCS was assessed during 
the second individual rating round (May 2019). In addition 
to the clinical variables, the panel selected a set of psycho-
social factors that may reduce the effectiveness of SCS and 
should therefore be included in the considerations for referral 
and selection for SCS. These factors were derived from scru-
tinizing the available literature, and a group discussion on 
expert panel members’ observations from clinical practice. 
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The shortlist of psychosocial factors included: lack of en-
gagement, dysfunctional coping, unrealistic expectations, 
inadequate daily activity level, problematic social support, 
secondary gain, psychological distress/mental health prob-
lems and unwillingness to reduce high-dose opioids (Beltrutti 
et al., 2004; Blackburn et al., 2016; Bruns & Disorbio, 
2009; Celestin, Edwards, & Jamison, 2009; Doleys, 2006; 
van Dorsten, 2006; Gybels et al., 1998; Paroli et al., 2018; 
Rosenberg, Schultz, Duarte, Rosen, & Raza, 2014; Shamji, 
Rodriguez, Shcharinsky, & Paul, 2016; Sparkes et al., 2010).
2.4 | Appropriateness calculations and 
statistical analysis
Appropriateness of (referral for) SCS was calculated using the 
mathematical rules that are typically applied in RUAM studies 
(Fitch et al., 2001). SCS was considered appropriate if the me-
dian score was between 7 and 9, and inappropriate if the median 
was between 1 and 3, without disagreement between panellists. 
Disagreement was defined as the situation in which at least one 
third of the panellists scored in each of the sections 1–3 and 7–9 
(Fitch et al., 2001). All other outcomes were deemed “equivo-
cal/uncertain”. Frequency tables and cross-tabulations were 
used to describe the appropriateness outcomes by clinical varia-
bles and specialty. All statistical analyses were performed using 
the IBM SPSS Statistics 26 software package (SPSS Inc.).
2.5 | Educational e-health tool
The panel results were used to develop an e-health tool that 
supports the education of healthcare professionals on the ap-
propriate referral and selection of patients with chronic pain 
F I G U R E  1  Flow diagram of the panel study
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for SCS. The tool combines the patient's clinical profile and 
psychosocial factors to an overall perspective on the appro-
priateness of (referral for) SCS. Details on the construction 
of the e-health tool are provided in the supporting materials. 
The tool was presented and pretested during various work-
shops (a.o. the biennial EFIC congress [Valencia, September 
2019] and the NSUKI Annual Scientific Meeting [Leeds, 
November 2019]). Based on the feedback from these meet-
ings, further refinements were made to the tool.
3 |  RESULTS
3.1 | Appropriateness and agreement
Overall, (referral for) SCS was considered appropriate in 16% 
of the clinical scenarios, and inappropriate in 23%. For the re-
maining 61%, the outcome was equivocal. Appropriateness fig-
ures by indication area and specialty are depicted in Figure 2.
Chronic low back and leg pain, CRPS and NPS show fairly 
similar appropriateness patterns, while for the small chapter 
of IPS (10 scenarios) no inappropriate indications are seen. 
The category “other specialists” shows the highest proportion 
of equivocal outcomes for all indication areas. There was full 
agreement (median scores in the same appropriateness cate-
gory) between the three specialities in 47% of the scenarios.
3.2 | Chronic low back and/or leg pain
Table  3 shows the appropriateness of (referral for) SCS for 
patients with CBLP by clinical variables. In the case of pre-
vious spinal surgery, appropriateness was higher if leg pain 
was more dominant, if the neuropathic component of the pain 
was larger and if there has been at least a partial or temporary 
response to a root block, TENS, radiofrequency and/or neuro-
pathic medication in the past. For anatomic abnormality, the 
highest appropriateness scores were seen for scar tissue and 
iatrogenic nerve lesion. For cases without previous spinal sur-
gery, the patterns for the clinical variables were similar, but 
appropriateness figures were consistently and proportionally 
lower. The impact of the positive factors was mostly cumula-
tive. For example, for patients with previous surgery and pre-
senting with predominant leg pain, appropriateness goes up 
from 39% to 58% if the type of pain is predominantly neuro-
pathic, and further increases to 83% if there had been a positive 
response to a root block. The patterns for inappropriateness 
largely mirrored those of the figures for appropriate outcomes.
3.3 | Complex regional pain syndrome
For patients with CRPS, (referral for) SCS was consid-
ered more frequently appropriate if the type of pain was 
neuropathic(-like) or ischaemic due to vasomotor distur-
bances, and if spread of pain was more limited (Table 4). In 
addition, there was a pronounced impact of a positive response 
to a previous nerve block and/or neuropathic medication on 
the perceived appropriateness of SCS. Inappropriateness was 
mainly seen in patients with nociceptive or widespread pain.
3.4 | Neuropathic pain syndromes
Of the 10 indications considered by the panel, traumatic nerve 
lesions and postsurgical pain had the highest appropriateness 
scores (both 33% of related scenarios), while postherpetic 
pain and brachial plexus injury with root avulsion were never 
considered an appropriate indication (mostly equivocal). For 
the other 6 indications, 17% of related scenarios were consid-
ered appropriate. The presence of predominant neuropathic 
pain significantly increased the perceived appropriateness 
of SCS (overall from 17% to 50%), while the addition of a 
previous positive response to a nerve block or neuropathic 
T A B L E  1  Absolute criteria for the consideration of SCS, selected by the expert panel
Inclusion criteria Exclusion criteria
• Age ≥ 18 years
• Chronic pain with a duration of least 6 months
• One of the following primary indications:
• Chronic low back/leg pain
• Complex regional pain syndrome
• Neuropathic pain syndrome
• Ischaemic pain syndrome
• Pain severity at least moderate (VAS ≥ 5) having a substantial 
impact on daily functioning and quality of life
• Insufficiently responding to appropriate trials of medication and/
or minimally invasive treatments (such as local anaesthetic nerve 
blocks) and/or experiencing intolerable side effects of these 
treatments
• No clear benefits of surgery expected
• Unwilling to have an implant
• Unable to manage the device
• Absolute contra-indications for active treatment (e.g. unfit for 
undergoing SCS, pregnancy, spine infection, coagulation disorder)
• Uncontrolled disruptive psychological or psychiatric disorder
• Ongoing alcohol and drug misuse
• Widespread pain
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medication further increased this figure to 75%. Details can 
be found in the supporting materials.
3.5 | Ischaemic pain syndromes
Refractory angina pectoris, ischaemic leg pain (Fontaine II-
III), Raynaud's disease and Buerger's disease were all con-
sidered an appropriate indication for SCS provided a positive 
response to a previous nerve block or neuropathic pain medi-
cation. In the case of no response to a previous block or medi-
cation, and for patients with ischaemic leg pain categorized 
as Fontaine IV, the outcome was equivocal.
3.6 | Psychosocial factors
After preparatory work by the psychologist panel-
lists, the panel agreed on a set of factors and related 
definitions that should guide the psychosocial evaluation of 
patients for whom SCS is considered an option (Table 5). 
Recommendations were specified by target group (refer-
rers/implanters). For referrers, classification in any of the 
moderate or severe categories (or comparable) should lead 
to consultation with a clinical psychologist or multidisci-
plinary team. For implanters, similar advice applied to the 
moderate category, but any outcome in the severe category 
was considered a strong contraindication for SCS, assum-
ing that this situation has been determined by a standard-
ized measurement or specialist clinical judgement. For both 
groups, a total lack of engagement was considered an abso-
lute contraindication.
3.7 | Educational e-health tool
The panel results were embedded in an educational e-health 
tool that allows creating a patient profile and seeing the 
T A B L E  2  Variables used to create the clinical scenarios (2nd round)
Chapter Variables Categories
CBLP 1. Previous spine surgery No; yes
2. Dominant location of pain Leg; back; mixed
3. Dominant type of pain Neuropathic (with sensory disturbances); neuropathic-like (without sensory 
disturbances); nociceptive; mixed
4. Anatomic abnormality Recurrent disc; scar tissue; iatrogenic nerve lesion; spinal/foraminal stenosis; spinal 
instability; none or not concordant with symptoms
5. Response to root block, TENS, 
epiduroscopy, radiofrequency and/or 
neuropathic pain medication
No clinically relevant response; at least partial/temporary effect to any of these regimens
CRPS 1. Dominant symptom Neuropathic pain (with sensory disturbances); neuropathic-like pain (without sensory 
disturbances); ischaemic pain/vasomotor disturbance; “pure” nociceptive pain; mixed
2. Response to sympathetic nerve 
block and/or neuropathic pain 
medication
No clinically relevant response; at least partial/temporary effect to any of these regimens
3. Spread of pain 1 limb; 2 upper or 2 lower limbs; 1 upper and 1 lower limb; 3 or more limbs
NPS 1. Nature/origin of pain Diabetic peripheral neuropathy; traumatic nerve lesion(s); post-surgical pain; post-
herpetic pain; phantom pain; stump pain; brachial plexus injury without root avulsion; 
brachial plexus injury with root avulsion; small fibre neuropathy; post-chemotherapy 
neuropathy
2. Dominant type of pain Neuropathic; nociceptive; mixed
3. Response to TENS, somatic sensory 
and/or autonomic nerve block and/or 
neuropathic pain medication
No clinically relevant response; at least partial/temporary effect to any of these regimens
4. Spread of pain Both legs affected; both legs and arms affected; mononeuritis only; not applicable
IPS 1. Nature/origin of pain Refractory angina pectoris; ischaemic leg pain (Fontaine II-III); ischaemic leg pain 
(Fontaine IV); Raynaud’s disease; Buerger’s disease
2. Response to sympathetic nerve 
block, TENS and/or neuropathic pain 
medication
No clinically relevant response; at least partial/temporary effect to any of these regimens
Abbreviations: CBLP, chronic low back/leg pain; CRPS, complex regional pain syndrome; IPS, ischaemic pain syndrome; NPS, neuropathic pain syndrome.
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appropriateness of (referral for) SCS. The tool starts with a 
check on the absolute criteria for the consideration of SCS 
(see Table 1), and continues with an assessment of the clini-
cal aspects (see Figure 3). If the outcome is appropriate or 
equivocal, the psychosocial profile needs to be completed 
(Figure 4). The combined outcomes of the clinical and psy-
chosocial aspects result in a final recommendation (referral/
SCS strongly recommended, recommended or not recom-
mended). For details on the calculations: see supporting 
materials.
The tool was presented and tested during workshops at 
congress meetings of EFIC and NSUKI, as well as some 
other (inter)national educational meetings, where it was re-
ceived with significant interest and even enthusiasm. Based 
on the feedback of participants, some adaptations and refine-
ments were made to the tool.
The e-health tool is freely available for healthcare profes-
sionals on: https://www.scsto ol.org/.
4 |  DISCUSSION
Although SCS has been used for 50 years in the management 
of chronic pain, there remain a number of uncertainties about 
its precise indications in daily clinical practice. This is partly 
due to a lack of high(er)-quality studies into the effectiveness 
of SCS for some indication areas, but also to the heterogene-
ity of the patient population within the largest indications of 
SCS such as neuropathic pain and persistent pain after spine 
surgery. Finally, the interaction between chronic pain and 
psychosocial factors as well as analgesic medication intake 
provide further layers of complexity. This in turn necessi-
tates careful balancing of relevant clinical and psychosocial 
characteristics.
The lack of high(er)-quality effectiveness studies espe-
cially relates to the mono- and polyneuropathies such as 
postsurgical and postherpetic pain, with the exception of 
painful diabetic polyneuropathy (van Beek et al., 2018; 
Slangen et al., 2014; de Vos et al., 2014). Efficacy of SCS 
in ischaemic pain syndromes has been shown in older stud-
ies, but considerable bias downgrades the quality of evi-
dence and makes these outcomes uncertain (Huygen et al., 
2019).
The RUAM proved to be helpful in establishing pa-
tient-specific appropriateness statements for 386 clinical 
scenarios. Despite the differences in panellists’ background, 
there was substantial agreement across the specialties 
(Figure 2). The panel outcomes constitute clear situations in 
which SCS is appropriate or inappropriate. However, there 
were also a considerable number of scenarios for which the 
outcome was equivocal, reflecting uncertainty about the po-
tential effectiveness of SCS. It should be mentioned that the 
appropriateness figures relate to a set of theoretical scenarios, 
and part of the ratings may be equivocal due to uncommon 
or less realistic cases. As demonstrated in previous RUAM 
studies, the proportion of equivocal/uncertain outcomes may 
therefore be lower in real clinical practice (e.g. Anselmetti 
et al., 2013; Schupfner et al., 2016).
F I G U R E  2  Appropriateness results by indication area and specialty of the panel members. Percentages of median scores in each of the 
sections 1–3 (inappropriate), 4–6 (equivocal) and 7–9 (appropriate). CBLP, chronic low back/leg pain; CRPS, complex regional pain syndrome; 
IPS, ischaemic pain syndrome; NPS, neuropathic pain syndrome. A, anaesthesiologists; N, neurosurgeons; O, other specialists (psychologist, 
physiotherapist, nurse specialist); T, total
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4.1 | Clinical factors
For all pain areas, a partial or temporary response to a pre-
vious root block, TENS and/or neuropathic pain medication 
consistently increased the appropriateness ratings for SCS. 
This is not directly supported by literature findings, but obvi-
ously reflects the panellists’ experiences in clinical practice. 
A second strong driver of appropriateness (except for IPS) 
was the neuropathic(-like) pain component. This is in line 
with the inclusion criteria for most clinical trials that took 
predominant neuropathic(-like) pain as a prerequisite for the 
consideration of SCS.
In our study, neuropathic pain (with sensory disturbances) 
generally scored higher than neuropathic-like pain (without 
sensory disturbances) as a predictor of suitability for neuro-
stimulation. Assuming that in the majority of patients with 
CBLP and CRPS there is more neuropathic-like pain than 
neuropathic pain, this is a remarkable finding. After all, there 
is good-quality evidence that neurostimulation is effective for 
both indications. The different outcomes for neuropathic and 
neuropathic-like pain may partly be explained by unfamiliar-
ity with the various definitions by the panel members, and we 
are therefore hesitant to emphasize this difference too much. 
At the same time, we advocate explicitly recognizing this dif-
ference because we want to emphasize that the indication for 
neurostimulation is not limited to neuropathic pain alone.
In patients with CBLP, the appropriateness scores were 
higher in those who had undergone spinal surgery. This is 
not surprising, as the efficacy of SCS in CBLP has predomi-
nantly been studied in patients with “failed back surgery syn-
drome”. However, a recent cohort study on high-frequency 
T A B L E  3  Appropriateness of (referral for) SCS by clinical 
variables for patients with chronic low back and/or leg pain. 
Appropriate indications; percentage of clinical scenarios by subgroup. 
Row totals per variable are 100%
Variables/categories
Previous 
surgery (%)
No previous 
surgery (%)
I E A I E A
Dominant location of pain
Leg 0 61 39 3 75 22
Mixed 23 48 29 25 60 15
Back 38 62 0 40 60 0
Dominant type of pain
Neuropathic 8 53 39 8 67 25
Neuropathic-like 3 64 33 11 72 17
Mixed 11 83 6 12 88 0
Nociceptive 88 12 0 88 12 0
Response to root block, TENS, RF and/or neuropathic pain medication
No 27 59 14 32 65 3
At least partial or temporary 17 54 29 17 63 20
Anatomic abnormality
Recurrent disc 14 63 23 14 72 14
Scar tissue 14 45 41 14 63 23
Iatrogenic nerve lesion 14 45 41 14 63 23
Spinal/foraminal stenosis 18 64 18 18 77 5
Spinal instability 50 50 0 59 41 0
None/not concordant with 
symptoms
23 72 5 27 68 5
Abbreviations: A, appropriate; E, equivocal; I, inappropriate.
Variables/categories
Inappropriate 
(%)
Equivocal 
(%)
Appropriate 
(%)
Dominant symptom
Neuropathic 0 50 50
Neuropathic-like 0 75 25
Ischaemic/vasomotor 0 62 38
Mixed 12 75 13
Nociceptive 38 62 0
Response to nerve block and/or neuropathic pain medication
No 15 80 5
At least partial or temporary 5 50 45
Spread of pain
One limb 0 50 50
Two upper or two lower limbs 10 70 20
One upper and one lower limb 0 70 30
Three or more limbs 30 70 0
T A B L E  4  Appropriateness by clinical 
variables for patients with complex regional 
pain syndrome. Percentage of clinical 
scenarios by variable. Row totals are 100%
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SCS in surgery-naïve patients suggests favourable results 
(Al-Kaisy et al., 2018; Kapural et al., 2015).
The appropriateness of SCS was considered higher when 
the pain was located more in the leg than in the back. This 
perception also relates to the design of several RCTs, where 
patients with predominant back pain were excluded (Kumar 
et al., 2007; North et al., 2005). However, a meta-analysis 
stratified by the location of CBLP pain did not find a statisti-
cal association between pain relief and the location of CBLP 
(Taylor, Desai, Rigoard, & Taylor, 2014).
The highest appropriateness scores were given to patients 
with scar tissue or iatrogenic nerve lesions, albeit that this 
cannot be supported by data from clinical studies or guideline 
recommendations. It seems worthwhile to explore this gen-
eral feeling with controlled well-powered studies. The panel 
outcomes for surgery-naïve patients with CBLP are largely 
in line with the results of a recent RUAM study into the ap-
propriate management of patients with persistent pain after 
previous spine surgery (Tronnier et al., 2019).
For patients suffering from CRPS, spread of pain is an im-
portant variable, with the highest appropriateness score given 
to patients with pain limited to one extremity. Most current 
guidelines and literature do not mention the impact of spread 
of pain on the efficacy of SCS. However, the two trials that 
have been conducted on SCS in CRPS included only patients 
with pain limited to one hand or one foot (Kemler et al., 2000), 
or to the lower limbs (Deer et al., 2017), indicating that the 
perceived relation between limited spread of pain and efficacy 
of SCS already existed in the pain specialist community.
For (other) NPS, the outcomes were mostly equivocal, 
tending to appropriate in patients with predominant neu-
ropathic pain and having had a temporary/partial response 
to a previous nerve block, TENS and/or neuropathic pain 
medication, and to inappropriate in the opposite scenarios. 
Although these appropriateness patterns were fairly straight-
forward, there is, as yet, no direct evidence from clinical tri-
als to support the panel recommendations. In the absence of 
evidence from clinical trials, we can sometimes use a more 
mechanism-based approach in decision making. It is, for 
example, generally accepted that in the case of nerve dam-
age, stimulation is only effective if applied proximal to the 
lesion. This is why a brachial plexus injury with root avul-
sion and other neuropathic conditions proximal to the DRG 
cannot be considered an appropriate indication (De Andrade 
et al., 2010; Sdrulla, Guan, & Raja, 2018; Sindou, Mertens, 
Bendavid, García-Larrea, & Mauguière, 2003).
For IPS, the expert panel indicated that SCS should always 
be considered an option, as the outcomes were never inappro-
priate. It should be noted that the panel was asked to assess the 
appropriateness of SCS in relation to pain reduction, and not to 
improve blood flow or reduce the risk of limb amputation. The 
panel's positive attitude towards SCS in IPS is corroborated 
by data from literature, reviewed by Ubbink and Vermeulen 
(2013). The panel outcomes for patients with ischaemic leg 
pain classified as Fontaine IV (equivocal) may be surprising as 
this condition is associated with ischaemic ulcers or gangrene 
for which SCS may seem less appropriate. However, data from 
a single-arm study suggest that SCS in patients with Fontaine 
III-IV lower limb critical ischemia may result in significant 
pain relief (Petrakis & Sciaccia, 2000).
T A B L E  5  Psychosocial factors judged relevant for the 
consideration of SCS in patients with chronic pain
Variables/categories and related definitions
Lack of engagement (no; partly; total)
Failing to attend appointments (offered by the neuromodulation 
or other services)
Failing to follow up on agreed recommendations, e.g. self-
referral to psychological therapy service
Non-compliance with treatment
Attending treatment (e.g. a pain management programme) but 
with a clear lack of engagement with the programme (e.g. 
frequently attending late, non-participation in group tasks, not 
completing homework tasks/exercise programme)
Dysfunctional coping (no or mild; moderate; severe)
Avoidance of movement/activity
Avoidance, misuse of medication/illegal drugs
Unrealistic expectations (no or mild; moderate; severe)
Total pain relief
Inability to articulate post-implant goals
Inadequate daily activity level (no or mild; moderate; severe)
Inconsistency between what patient reports they can do and what 
they have shown they can do, e.g. patient reporting they cannot 
get out of bed for short period but attends all appointments
Low self-efficacy
Lack of, or very restricted, participation in activities of daily 
living
Problematic social support (no or mild; moderate; severe)
No social/family support
Poor quality support, e.g. patient reports they have friends/family 
but are unreliable, patient has not sought their support
Secondary gain (no; probably; yes or very likely)
Litigation
Presence of factors that mean that the patient might 
(unconsciously) have an incentive for remaining “ill”
Psychological distress/mental health problems (no or mild; 
moderate; severe)
For example: low mood, anxiety, panic disorder, post-traumatic 
stress disorder
Unwilling to reduce high-dose opioids (no, or not applicable; 
probably; very likely)
Use of high-dose opioids, and unwilling to reduce these to 
an acceptable level according to the opinion of the treating 
physician
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F I G U R E  3  User interface of the e-health tool (clinical aspects)
F I G U R E  4  User interface of the e-health tool (psychosocial factors)
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4.2 | Psychosocial factors
The panel selected and defined a set of eight psychosocial 
factors that are relevant when considering referral or selec-
tion for SCS. These factors were based on the (fragmentary) 
evidence from studies (Beltrutti et al., 2004; Blackburn et al., 
2016; Bruns & Disorbio, 2009; Celestin et al., 2009; Doleys, 
2006; van Dorsten, 2006; Gybels et al., 1998; Paroli et al., 
2018; Rosenberg et al., 2014; Shamji et al., 2016; Sparkes 
et al., 2010) and expert panel members’ observations from 
clinical practice. The current checklist and related recom-
mendations should be seen as a first step in the systematic 
evaluation of psychosocial aspects by nonexperts. In this 
phase, simplicity and (time)efficiency of the checklist have 
prevailed over comprehensiveness of the aspects included.
4.3 | Strengths and limitations
Our study has produced a set of patient-specific recommen-
dations on the appropriateness of SCS, combining relevant 
clinical and psychosocial aspects. The inclusion of these 
recommendations in an easy-to-use educational e-health tool 
may help to improve the quality of (pre)selection of patients 
with chronic pain for SCS.
The most important limitations of this study are related to 
the panel composition and the subjective nature of the panel 
recommendations. We have included only healthcare profes-
sionals who are actively involved in patient selection for SCS. 
We have chosen this approach because we considered practice 
experience as a prerequisite to assess the appropriateness of 
SCS for the various scenarios. However, for assessing the appli-
cability of the panel recommendations in daily practice, the in-
volvement of referring physicians will be absolutely necessary.
The absence of results from clinical studies for many of 
the clinical scenarios means that expert opinion was often 
the best available evidence. Validation studies are therefore 
mandatory, and have already been initiated. RUAM studies in 
other disease areas have demonstrated good predictive value 
of the panel recommendations for eventual patient outcomes 
(Garcia-Gutierrez et al., 2014; Gimeno García et al., 2012; 
Lawson et al., 2012; Sekhri et al., 2008; Tombal et al., 2013).
Finally, the list of (potential) indications for SCS in chronic 
pain we have considered in this study is not exhaustive. We 
have concentrated on the most prevalent indications, and 
other conditions may be added by the panel in future updates.
4.4 | Conclusions
Using the RUAM, a European multidisciplinary panel for-
mulated patient-specific recommendations on the appropriate 
referral and selection of patients with chronic pain for the 
consideration of SCS. The e-health tool may help physicians 
learn to apply an integrated approach of clinical and psycho-
social factors.
The predictive value of the panel recommendations for 
patient outcomes needs further research.
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